Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
about
SCT in Jehovah's Witnesses: the bloodless transplantSuccessful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopeniaHaematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experienceAllogeneic hematopoietic cell transplantation: the state of the artClinical observation of factors in the efficacy of blood component transfusion in patients following hematopoietic stem cell transplantation.Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review.Development of reduced-intensity hematopoietic stem cell transplantation in the National Cancer Center Hospital, Japan.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.Reduced-intensity conditioned allogeneic SCT in adults with AML.Trends in United States blood collection and transfusion: results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey.The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure.Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation.A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients.A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level.Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation.Transfusions after nonmyeloablative or reduced-intensity conditioning regimens.
P2860
Q28267204-506CF506-8029-4D62-8A61-E6176B2F468BQ28288837-B9DDEC92-2663-4F3C-9BBF-1EE7C84FF55CQ33360252-099D3DB6-B848-492D-89C6-F92B89EA60C7Q33363445-0307DA2C-5D6A-4DA8-8E2E-58A18CF6282FQ33763908-91954E0E-2021-4F45-B2D7-ECEEE04634E0Q34145155-C30DC4C1-893C-4C38-A0D7-3B1A2F07A218Q34304959-31A7D97D-98A9-4440-8265-34764108446AQ34440672-2929EB05-242C-46CF-A0EC-50C4A65DD551Q35071096-7B23094C-4DC2-44E0-828B-1FFAC07B37A9Q35201918-C9A945A3-4477-4306-85AE-821D2D0428FEQ35690761-B64E55E8-A17C-448A-A71B-6321D6EAD507Q36182976-6A42079D-4200-41CE-A290-3E5221CC800EQ36746447-DFAC3063-7062-4FB8-80D7-74E6B9B9FCBAQ37928443-626B3A79-EF07-4DBA-904A-E9F5AD0CD183Q38366632-1C037EF2-2145-48FC-8DD3-471441694314Q38853163-255D138C-D6D2-437A-AE5D-03B04662BC92Q40359224-3D5089C9-A2B7-45E9-9F23-663EECCD72DDQ40548332-92C65622-44F9-42D2-BD8B-A550FA8ED7FFQ40563365-CD4C9BEF-1E10-4C66-906D-B33B819AC796Q44733418-7C56A9F0-8E72-49D1-BFCE-89B126230D8DQ45010717-0560F915-62F7-4773-9CD0-4C2A5A825499Q46693823-07C8906F-4627-4430-8003-7C4DF7F5652CQ46774796-0B2D18EB-4561-4AB8-96BF-F9C9116146E7Q47885679-26858A61-D737-491D-8CC4-3E22AC6055CDQ50517429-390B5388-0C2E-4A8B-8824-A880A49C7B0FQ53593916-5BA447D1-17CA-4F99-9EA2-49F90F71507F
P2860
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Decreased transfusion requirem ...... s from HLA-identical siblings.
@en
Decreased transfusion requirem ...... s from HLA-identical siblings.
@nl
type
label
Decreased transfusion requirem ...... s from HLA-identical siblings.
@en
Decreased transfusion requirem ...... s from HLA-identical siblings.
@nl
prefLabel
Decreased transfusion requirem ...... s from HLA-identical siblings.
@en
Decreased transfusion requirem ...... s from HLA-identical siblings.
@nl
P2093
P1433
P1476
Decreased transfusion requirem ...... s from HLA-identical siblings.
@en
P2093
B M Sandmaier
D G Maloney
F Weissinger
W I Bensinger
P304
P356
10.1182/BLOOD.V98.13.3584
P407
P577
2001-12-01T00:00:00Z